Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of the central nervous system ...

Why Warren Buffett was selling stocks, Marvell’s outlook fails to wow Wall Street, and more news to start your day.

Normalised earnings before interest, tax, depreciation and amortisation (EBITDA) from commercial pharmaceuticals grew 13% ...

Citi analyst Daniel Grosslight keeps a Sell rating on Hims & Hers (HIMS) with a $27 price target after Novo Nordisk (NVO) announced ...